Clinical Trials Logo

Alzheimer Disease, Early Onset clinical trials

View clinical trials related to Alzheimer Disease, Early Onset.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03514875 Withdrawn - Clinical trials for Mild Cognitive Impairment

Effects of Mitochondrial-targeted Antioxidant on Mild Cognitive Impairment (MCI) Patients

Start date: November 11, 2019
Phase: N/A
Study type: Interventional

Neurodegenerative diseases such as Mild Cognitive Impairment, Alzheimer's, and dementia affect millions of Americans. Although these diseases are heavily researched, there is very little research examining the impact of attenuated carotid artery endothelial function and cerebrovascular blood flow on cognitive function. This is surprising, as cerebrovascular oxygenation has been shown to be strongly associated with reduced cognitive function and the pathogenesis of neurodegenerative diseases. For example, hypertension, diabetes, and high cholesterol have been shown to increase the risk of Alzheimers related dementia. Therefore, the purpose of this proposed study will be to examine the effects of MitoQ supplementation on carotid artery vasodilatory function and cerebrovascular blood flow in those suffering from Mild Cognitive Impairment (MCI). MitoQ is a mitochondria-targeting antioxidant that can improve nitric oxide production in the blood vessel, which should improve endothelial function, and thus cerebrovascular blood flow.